$80 million class settlement for class of end-payers, led by our clients, Wisconsin BC/BS and Aetna, which puchased Cardizem CD

Case Abstract
Negotiated an $80 million settlement for consumers and third party payers who overpaid for drug after brand manufacturer supressed generic competition.

Client
Class of end-payers, led by our clients, Wisconsin BC/BS and Aetna, which puchased Cardizem CD

Case Name
In re: Cardizem CD Antitrust Litig., 105 F.Supp.2d 618 (E.D. Mich. 2000), affirmed, 332 F.3d 896 (6th Cir. 2003), cert. denied, 125 S.Ct. 307 (2004); and In re: Cardizem CD Antitrust Litig., 218 F.R.D. 508 (E.D. Mich. 2003), appeal dismissed, 391 F.3d 812 (6th Cir. 2004), cert. denied, 125 S.Ct. 2297 (2005).

Result
$80 million class settlement.

Case Details
Lowey Dannenberg invalidated long-established tactics to delay generic drug competition, as lead counsel for a class headed by Aetna and WellPoint Wisconsin. After five years of litigation, we negotiated a settlement of $80 million for consumers and third party payers. Judge Nancy Edmunds of the Eastern District of Michigan wrote that we "aggressively prosecuted [the case] with the utmost skill, courtesy, and professionalism." Richard Cohen, who argued successfully twice before the 6th Circuit Court of Appeals to affirm judgments for plaintiffs in the case, and Peter St. Phillip were the principal prosecutors.